Description

Mass Construction (LGD-4033 + MK-677 + YK-11) Parenteral Solution  – Product Information

Mass Construction is an Parenteral Solutions research compound, that combines LGD-4033, MK-677, and YK-11 to explore their potential synergistic effects. This unique blend is formulated for research purposes only and is intended for controlled laboratory investigations. By leveraging the distinct mechanisms of action of each compound, Mass Construction Parenteral Solutions offers a comprehensive approach to studying muscle growth and overall body composition.

• Mass Construction consists of 30mg LGD-4033, 50mg MK-677 Ibutamoren, and 20mg YK-11.
• Mass Construction is offered in 100mg per ml for 10ml, totaling 1000mg.

LGD-4033

Ligandrol is a novel nonsteroidal oral selective androgen receptor modulator currently being investigated in research as a potential treatment for conditions relating to muscle dystrophy and osteoporosis.

Mass Construction Parenteral Solutions – Recent studies investigated the effects of LGD 4033 on muscle tissue in ovariectomized rats. A daily dose of LGD was administered and calculated according to the body weight of each individual rat at the onset of the study. Results and changes were noted as soon as week 2, the control group having weighed significantly less than rats undergoing LGD treatment. This difference remained until the end of the study, irrespective of LGD treatments. Additionally, the LGD treatments resulted in a higher number of capillaries in all muscles studied. Longer randomized trials and research could potentially evaluate its efficacy in improving physical function and health outcomes in select populations.

MK-677 Ibutamoren

A recent study set out to investigate the effects of MK-677 as a Ghrelin mimetic on body composition and clinical outcomes in healthy older adults. It was found that MK-677 enhanced fluctuating growth hormone secretion and markedly increased fat free-mass over a 12-month period. More extensive research and randomized trials could potentially evaluate its efficacy in improving physical function and health outcomes in select populations.

YK-11

A recent study has shown that YK11, a selective androgen receptor myostatin inhibitor, accelerates the expression of Follistatin in mice. Follistatin is a myostatin and activin-binding protein naturally found in the human body and has been used as a treatment for several degenerative muscle diseases. When follistatin levels are raised, myostatin levels will be inhibited. Inhibition of myostatin results in increased muscle mass and improved strength.

This study revealed that mice with low levels of myostatin have twice the amount of muscle mass compared to mice with high levels of myostatin. This shows the massive potential research implications of the strong anabolic effects that YK-11 can possess.